브롤루시주맙: 두 판 사이의 차이
잔글 →관련 연구 |
잔글 →관련 연구 |
||
| 6번째 줄: | 6번째 줄: | ||
== 관련 연구 == | == 관련 연구 == | ||
* [[OSPREY]]<ref>Dugel PU et al. Brolucizumab vs Aflibercept in Participants with wAMD : A Randomized Trial. ''Ophthalmology''. 2017 Sep;124(9):1296-1304. [https://pubmed.ncbi.nlm.nih.gov/28551167/ 연결]</ref> | * [[OSPREY]]<ref>Dugel PU et al. Brolucizumab vs Aflibercept in Participants with wAMD : A Randomized Trial. ''Ophthalmology''. 2017 Sep;124(9):1296-1304. [https://pubmed.ncbi.nlm.nih.gov/28551167/ 연결]</ref> | ||
* [[HAWK]] | * [[HAWK and HARRIER]]<ref>Dugel PU et al; HAWK and HARRIER Study Investigators. HAWK and HARRIER : P3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for wAMD. ''Ophthalmology''. 2020 Jan;127(1):72-84. [https://pubmed.ncbi.nlm.nih.gov/30986442/ 연결]</ref> | ||
{{참고}} | {{참고}} | ||